Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Axel Svedbom, Johan Dalén, Christopher M Black & Sumesh Kachroo. (2017) Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. Patient Preference and Adherence 11, pages 95-106.
Read now
Read now
J Nagel, P Geborek, T Saxne, G Jönsson, M Englund, IF Petersson, J-Å Nilsson & MC Kapetanovic. (2015) The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scandinavian Journal of Rheumatology 44:4, pages 271-279.
Read now
Read now
H Wadström, JK Eriksson, M Neovius, J Askling & on behalf of the ARTIS* Study Group. (2015) How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?. Scandinavian Journal of Rheumatology 44:1, pages 22-28.
Read now
Read now
H Ohlsson & J Merlo. (2011) Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009: comments on the article by M Neovius et al. Scandinavian Journal of Rheumatology 40:3, pages 243-244.
Read now
Read now
Articles from other publishers (37)
J. Nagel, G. Jönsson, J-Å. Nilsson, C. Manuswin, M. Englund, T. Saxne & M.C. Kapetanovic. (2023) Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis. Vaccine 41:2, pages 504-510.
Crossref
Crossref
Gabriella Bröms, Sonia Friedman, Seoyoung C Kim, Mollie E Wood, Sonia Hernandez-Diaz, Gregory Brill, Brian T Bateman, Krista F Huybrechts & Rishi J Desai. (2021) The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. Inflammatory Bowel Diseases 27:9, pages 1427-1434.
Crossref
Crossref
Marios Rossides, Susanna Kullberg, Anders Eklund, Johan Grunewald & Elizabeth V. Arkema. (2020) Sarcoidosis diagnosis and treatment in Sweden: A register-based assessment of variations by region and calendar period. Respiratory Medicine 161, pages 105846.
Crossref
Crossref
Mark Tatangelo, George Tomlinson, J. Michael Paterson, Vandana Ahluwalia, Alex Kopp, Tara Gomes, Nick Bansback & Claire Bombardier. (2019) Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage. JAMA Network Open 2:12, pages e1917053.
Crossref
Crossref
Linnea Oldsberg, Göran Garellick, Ingrid Osika Friberg, Anke Samulowitz, Ola Rolfson & Szilárd Nemes. (2019) Geographical variations in patient-reported outcomes after total hip arthroplasty between 2008 - 2012. BMC Health Services Research 19:1.
Crossref
Crossref
Petter Malmborg, Natalia Mouratidou, Michael C Sachs, Ulf Hammar, Hamed Khalili, Martin Neovius, Anders Hjern, Karin E Smedby, Anders Ekbom, Johan Askling, Jonas F Ludvigsson & Ola Olén. (2019) Effects of Childhood-onset Inflammatory Bowel Disease on School Performance: A Nationwide Population-based Cohort Study Using Swedish Health and Educational Registers. Inflammatory Bowel Diseases 25:10, pages 1663-1673.
Crossref
Crossref
Evelien Moorkens, Steven Simoens, Per Troein, Paul Declerck, Arnold G. Vulto & Isabelle Huys. (2019) Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting. BioDrugs 33:3, pages 285-297.
Crossref
Crossref
Daniel C. Baumgart, Laurent Misery, Sue Naeyaert & Peter C. Taylor. (2019) Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology 10.
Crossref
Crossref
Jonas F. Ludvigsson, Martin Mahl, Michael C. Sachs, Jan Björk, Karl Michaelsson, Anders Ekbom, Johan Askling, Ann-Sofie Backman & Ola Olén. (2019) Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014. American Journal of Gastroenterology 114:2, pages 291-304.
Crossref
Crossref
Petra Weimers, Jonas Halfvarson, Michael C Sachs, Rachel Saunders-Pullman, Jonas F Ludvigsson, Inga Peter, Johan Burisch & Ola Olén. (2019) Inflammatory Bowel Disease and Parkinson’s Disease: A Nationwide Swedish Cohort Study. Inflammatory Bowel Diseases 25:1, pages 111-123.
Crossref
Crossref
Åsa H. Everhov, Jonas Halfvarson, Pär Myrelid, Michael C. Sachs, Caroline Nordenvall, Jonas Söderling, Anders Ekbom, Martin Neovius, Jonas F. Ludvigsson, Johan Askling & Ola Olén. (2018) Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. Gastroenterology 154:3, pages 518-528.e15.
Crossref
Crossref
Caroline Nordenvall, Oda Rosvall, Matteo Bottai, Åsa H Everhov, Petter Malmborg, Karin E Smedby, Anders Ekbom, Johan Askling, Jonas F Ludvigsson, Pär Myrelid & Ola Olén. (2018) Surgical Treatment in Childhood-onset Inflammatory Bowel Disease–A Nationwide Register-based Study of 4695 Incident Patients in Sweden 2002-2014. Journal of Crohn's and Colitis 12:2, pages 157-166.
Crossref
Crossref
J. F. Ludvigsson, K. Büsch, O. Olén, J. Askling, K. E. Smedby, A. Ekbom, E. Lindberg & M. Neovius. (2017) Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study. BMC Gastroenterology 17:1.
Crossref
Crossref
M. Eberhardson, J. K. Söderling, M. Neovius, T. Cars, P. Myrelid, J. F. Ludvigsson, J. Askling, A. Ekbom & O. Olén. (2017) Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study. Alimentary Pharmacology & Therapeutics 46:6, pages 589-598.
Crossref
Crossref
Masahiro Tada, Kentaro Inui, Yuko Sugioka, Kenji Mamoto, Tadashi Okano, Shohei Anno & Tatsuya Koike. (2017) Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study. Rheumatology International 37:6, pages 999-1005.
Crossref
Crossref
Paul S. Calara, Rikard Althin, Katarina Steen Carlsson & Marcus Schmitt-Egenolf. (2017) Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients. BioDrugs 31:1, pages 75-82.
Crossref
Crossref
Polina Putrik, Sofia Ramiro, Elisabeth Lie, Andras P. Keszei, Tore K. Kvien, Désirée van der Heijde, Robert Landewé, Till Uhlig & Annelies Boonen. (2016) Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. Rheumatology 55:7, pages 1217-1224.
Crossref
Crossref
Paul S. Calara, Jenny M. Norlin, Rikard Althin, Katarina Steen Carlsson & Marcus Schmitt-Egenolf. (2016) Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice. BioDrugs 30:2, pages 145-151.
Crossref
Crossref
M. Tada, K. Inui, Y. Sugioka, K. Mamoto, T. Okano, T. Koike & H. Nakamura. (2015) Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis—results from the TOMORROW study. Osteoporosis International 27:2, pages 729-735.
Crossref
Crossref
Jennifer F. Waljee. 2016. Clinical Management of the Rheumatoid Hand, Wrist, and Elbow. Clinical Management of the Rheumatoid Hand, Wrist, and Elbow
53
60
.
Robert A. Lee & Daniel B. Eisen. (2015) Treatment of hidradenitis suppurativa with biologic medications. Journal of the American Academy of Dermatology 73:5, pages S82-S88.
Crossref
Crossref
Jonas K Eriksson, Johan A Karlsson, Johan Bratt, Ingemar F Petersson, Ronald F van Vollenhoven, Sofia Ernestam, Pierre Geborek & Martin Neovius. (2015) Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Annals of the Rheumatic Diseases 74:6, pages 1094-1101.
Crossref
Crossref
M Neovius, E V Arkema, H Olsson, J K Eriksson, L E Kristensen, J F Simard & J Askling. (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Annals of the Rheumatic Diseases 74:2, pages 354-360.
Crossref
Crossref
Stephen M. Campbell, Brian Godman, Eduardo Diogene, Jurij Fürst, Lars L. Gustafsson, Sean MacBride-Stewart, Rickard E. Malmström, Hanne Pedersen, Gisbert Selke, Vera Vlahović-Palčevski, Menno van Woerkom, Durhane Wong-Rieger & Björn Wettermark. (2015) Quality Indicators as a Tool in Improving the Introduction of New Medicines. Basic & Clinical Pharmacology & Toxicology 116:2, pages 146-157.
Crossref
Crossref
Kristin Waldenlind, Jonas K Eriksson, Bernhard Grewin & Johan Askling. (2014) Validation of the rheumatoid arthritis diagnosis in the Swedish National patient register: a cohort study from Stockholm County. BMC Musculoskeletal Disorders 15:1.
Crossref
Crossref
Polina Putrik, Sofia Ramiro, Tore K Kvien, Tuulikki Sokka, Till Uhlig & Annelies Boonen. (2014) Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?. Annals of the Rheumatic Diseases 73:11, pages 2010-2021.
Crossref
Crossref
Polina Putrik, Sofia Ramiro, Tore K Kvien, Tuulikki Sokka, Milena Pavlova, Till Uhlig & Annelies Boonen. (2014) Inequities in access to biologic and synthetic DMARDs across 46 European countries. Annals of the Rheumatic Diseases 73:1, pages 198-206.
Crossref
Crossref
K. Büsch, J. F. Ludvigsson, K. Ekström-Smedby, A. Ekbom, J. Askling & M. Neovius. (2014) Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Alimentary Pharmacology & Therapeutics 39:1, pages 57-68.
Crossref
Crossref
A. Kalkan, E. Hallert, L. Bernfort, M. Husberg & P. Carlsson. (2013) Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden. Rheumatology 53:1, pages 153-160.
Crossref
Crossref
Johan A Karlsson, Martin Neovius, Jan-Åke Nilsson, Ingemar F Petersson, Johan Bratt, Ronald F van Vollenhoven, Sofia Ernestam & Pierre Geborek. (2013) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Annals of the Rheumatic Diseases 72:12, pages 1927-1933.
Crossref
Crossref
Thomas Cars, Björn Wettermark, Rickard E. Malmström, Gunnar Ekeving, Bo Vikström, Ulf Bergman, Martin Neovius, Bo Ringertz & Lars L. Gustafsson. (2013)
Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi‐Automatic Methods Using Anti‐
TNF
Therapy as Model
. Basic & Clinical Pharmacology & Toxicology 112:6, pages 392-400.
Crossref
Crossref
Jonas K. Eriksson, Martin Neovius, Sofia Ernestam, Staffan Lindblad, Julia F. Simard & Johan Askling. (2013) Incidence of Rheumatoid Arthritis in Sweden: A Nationwide Population‐Based Assessment of Incidence, Its Determinants, and Treatment Penetration. Arthritis Care & Research 65:6, pages 870-878.
Crossref
Crossref
Julia F. Simard, Martin Neovius & Johan Askling. (2012) Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: Drug‐specific comparisons in the Swedish Biologics Register. Arthritis & Rheumatism 64:11, pages 3502-3510.
Crossref
Crossref
Polina Putrik, Tuulikki Sokka, Sofia Ramiro & Annelies Boonen. (2012) Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): Lessons from QUEST RA. Best Practice & Research Clinical Rheumatology 26:5, pages 705-720.
Crossref
Crossref
C.M. Grönhagen, C.M. Fored, M. Linder, F. Granath & F. Nyberg. (2012) Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. British Journal of Dermatology 167:2, pages 296-305.
Crossref
Crossref
Ebba K. LindqvistLynn R. GoldinOla LandgrenCecilie BlimarkUlf-Henrik MellqvistIngemar Turesson, Anders Wahlin, Magnus BjörkholmSigurdur Y. Kristinsson. (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:24, pages 6284-6291.
Crossref
Crossref
R. Windt, G. Glaeske & F. Hoffmann. (2011) Versorgung mit TNF-α-Blockern und regionale Unterschiede im Jahr 2010Prescription of TNF-alpha inhibitors and regional differences in 2010. Zeitschrift für Rheumatologie 70:10, pages 874-881.
Crossref
Crossref